Super-globuling for in vivo extended lifetimes
AssigneeRedCell, Inc.
InventorsPhilippe Pouletty, Christine Pouletty
Life of this patent
Estimating the term…
Abstract
First and second compounds are provided, where the first compound is administered to a mammalian host into blood for covalent bonding to blood components, where the components have an extended lifetime in the blood stream. The first compound comprises an active functionality and an agent of interest or a first binding entity. A second compound may be subsequently administered to the patient, which comprises a second binding entity, complementary to the first binding entity and an agent of interest. By virtue of binding to long-lived blood components, the half-life of the agent of interest is greatly extended in vivo.
Claims15
A method for extending the lifetime of a therapeutic agent of interest having a molecular weight of less than 5 kDa, said method comprising:
- administering to the vascular system of a mammalian host a compound comprising a reactive functional group which reacts with proteins to form stable covalent bonds, said reactive functional group being joined to said therapeutic agent of interest, whereby said reactive functional group reacts with at least one of mobile protein and cells of the vascular system to produce at least one of modified mobile protein and modified cells, wherein said reactive functional group reacts with a functional group on said protein or cells to form a member of the group consisting of amide, ester, imine, thioether, disulfide and substituted amine:
- wherein said therapeutic agent of interest is added in an amount effective to achieve its therapeutic function over an extended period of time.
A method for extending the lifetime of a naturally occurring organic compound having a molecular weight of less than 5 Kda, said method comprising:
- administering to the vascular system of a mammalian host a compound comprising a reactive functional group which reacts with proteins to form stable covalent bonds, said reactive functionaal group being joined to said naturally occurring organic compound, where said naturally occurring compound is a therapeutic agent whereby said reactive functional group is a carboxylate ester which reacts with at least one of mobile protein and cells of the vascular system to produce at least one of modified mobile protein and modified cells, wherein said naturally occurring compound is added in an amount effective to achieve its therapeutic function over an extended period of time.
A method for extending the lifetime of a therapeutic agent of interest having a molecular weight of less than about 2.5 kDa, said method comprising:
- administering to the vascular system of a mammalian host a compound, said compound comprising a reactive functional group which reacts with proteins to form stable covalent bonds wherein said reactive functional group is joined to said therapeutic agent of interest, whereby said reactive functional group reacts with at least one of mobile proteins or cells of the vascular system to produce one of modified mobile proteins or modified cells, wherein said functional group reacts with a functional group on said protein or cell to form a member of the group consisting of amide, ester, imine, thioether, disulfide or substituted amine;
- wherein said therapeutic agent of interest is added in an amount to maintain an effective therapeutic concentration over an extended period of time.
A method for extending the lifetime of a naturally occurring organic compound having a molecular weight of less than about 5 kDa, said method comprising:
- administering a bolus to the vascular system of a mammalian host a compound, said compound comprising a reactive functional group which reacts with proteins to form stable covalent bonds wherein said reactive functinonal group is joined to said naturally occurring organic compound, wherein said naturally occurring organic compound is a therapeutic agent, whereby said reactive functional group reacts with at least one of mobile proteins and cells of the vascular system to produce one of modified mobile proteins or modified cells, wherein said functional group reacts with a functional group on said protein or cell to form a member of the group consisting of amide, ester, imine, thioether, disulfide or substituted amine;
- wherein said naturally occurring compound is added in an amount to maintain an effective therapeutic concentration over an extended period of time.
Dependencies are inferred from the claim text.